Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-04-20
|
tenofovir alafenamide (TAF) |
hepatitis B |
3 |
Gilead Sciences (USA - CA) |
Infectious diseases |
2017-04-20
|
NV556 |
NASH (non-alcoholic steatohepatitis) |
preclinical |
Neurovive Pharmaceutical (Sweden) |
Liver diseases - Hepatic diseases |
2017-04-19
|
Prostvac® (rilimogene), in combination treatment with Yervoy® (ipilimumab) and/or Opdivo® (nivolumab) |
localized prostate cancer |
2 |
Bavarian Nordic (Denmark) BMS (USA - NY) |
Cancer - Oncology |
2017-04-19
|
Ocaliva® (obeticholic acid - OCA) |
primary biliary cirrhosis, primary biliary cholangitis |
3 |
Intercept Pharmaceuticals (USA - NY) |
Autoimmune diseases- Liver diseases - Hepatic diseases |
2017-04-18
|
burosumab - recombinant human monoclonal IgG1 antibody for fibroblast growth factor 23/KRN23 |
X-linked Hypophosphatemia |
3 |
Ultragenyx Pharmaceutical (USA - CA) Kyowa Hakko Kirin (Japan) |
Rare diseases - Genetic diseases - Metabolic diseases |
2017-04-18
|
pegunigalsidase alfa (PRX-102 - alpha-galactosidase-A) |
Fabry disease |
preclinical |
Protalix BioTherapeutics (Israel) |
Rare diseases - Genetic diseases |
2017-04-17
|
elobixibat |
chronic constipation |
2 |
Albireo Pharma (USA - MA) Albireo (Sweden) EA Pharma (Japan) |
Gastrointestinal diseases - Digestive diseases |
2017-04-11
|
compounds targeting Zika virus |
Zika virus infection |
preclinical |
Abivax (France) |
Infectious diseases |
2017-04-11
|
4SC-202 |
|
preclinical |
4SC (Germany) |
Cancer - Oncology |
2017-04-11
|
lefamulin (BC 3781) |
community-acquired bacterial pneumonia (CABP) |
3 |
Nabriva Therapeutics (Austria) |
Infectious diseases |
2017-04-11
|
INO-4201 |
Ebola fever |
1 |
Inovio Pharmaceuticals (USA - PA) |
Infectious diseases |
2017-04-10
|
IVA337 - lanifibranor - 1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid) |
systemic sclerosis |
2 |
Inventiva Pharma (France) |
Rare diseases - Autoimmune diseases |
2017-04-10
|
demcizumab |
first-line metastatic pancreatic cancer |
2 |
OncoMed Pharmaceuticals (USA - CA) Celgene (USA - NJ) |
Cancer - Oncology |
2017-04-07
|
fruquintinib |
non-small cell lung cancer (NSCLC), renal cell cancer |
preclinical |
Hutchison China MediTech Limited "ChiMed" (China) |
Cancer - Oncology |
2017-04-07
|
sulfatinib |
|
preclinical |
Hutchison China MediTech Limited "ChiMed" (China) |
Cancer - Oncology |
2017-04-06
|
ACH-4471 |
paroxysmal nocturnal hemoglobinuria (PNH) |
2 |
Achillion Pharmaceuticals (USA - CT) |
Rare diseases - Immunological diseases |
2017-04-06
|
ASN120290 (formerly known as ASN-561) |
dementia |
1 |
Asceneuron (Switzerland) |
CNS diseases - Neurodegenerative diseases |
2017-04-05
|
TAK-003 (live-attenuated tetravalent dengue vaccine candidate) |
dengue fever |
3 |
Takeda Pharmaceutical (Japan) |
Infectious diseases |
2017-04-05
|
filgotinib |
psoriatic arthritis |
2 |
Galapagos (Belgium) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2017-04-05
|
Botox® (onabotulinumtoxinA) |
major depressive disorder (MDD) |
2 |
Allergan (Ireland) |
CNS diseases - Mental diseases |